LABD vs. XTJL
LABD (Direxion Daily S&P Biotech Bear 3x Shares) and XTJL (Innovator U.S. Equity Accelerated Plus ETF - July) are both Leveraged Equities funds. LABD is passively managed, while XTJL is actively managed. Over the past 3 years, LABD returned -49.85%/yr vs 14.68%/yr for XTJL. At a correlation of -0.54, they often move in opposite directions. LABD charges 1.06%/yr vs 0.79%/yr for XTJL.
Performance
LABD vs. XTJL - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, LABD achieves a -29.83% return, which is significantly lower than XTJL's 5.36% return.
LABD
- 1D
- -4.73%
- 1M
- 4.70%
- YTD
- -29.83%
- 6M
- -31.22%
- 1Y
- -80.27%
- 3Y*
- -49.85%
- 5Y*
- -41.45%
- 10Y*
- -56.11%
XTJL
- 1D
- 0.00%
- 1M
- 1.16%
- YTD
- 5.36%
- 6M
- 6.38%
- 1Y
- 15.64%
- 3Y*
- 14.68%
- 5Y*
- —
- 10Y*
- —
LABD vs. XTJL - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
LABD Direxion Daily S&P Biotech Bear 3x Shares | -29.83% | -70.07% | -21.43% | -41.77% | -32.68% | 42.52% |
XTJL Innovator U.S. Equity Accelerated Plus ETF - July | 5.36% | 15.42% | 14.43% | 25.72% | -15.66% | 7.28% |
Correlation
The correlation between LABD and XTJL is -0.46, meaning they tend to move in opposite directions. This is especially valuable for risk management - when one declines, the other has historically tended to hold steady or rise.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.46 |
Correlation (3Y) Calculated over the trailing 3-year period | -0.49 |
Correlation (All Time) Calculated using the full available price history since Jul 2, 2021 | -0.54 |
The correlation between LABD and XTJL has been stable across timeframes, ranging from -0.54 to -0.46 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LABD vs. XTJL — Risk / Return Rank
LABD
XTJL
LABD vs. XTJL - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Direxion Daily S&P Biotech Bear 3x Shares (LABD) and Innovator U.S. Equity Accelerated Plus ETF - July (XTJL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| LABD | XTJL | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -3.18 | ||
| Sortino ratioReturn per unit of downside risk | -5.36 | ||
| Omega ratioGain probability vs. loss probability | 0.75 | 1.46 | -0.71 |
| Calmar ratioReturn relative to maximum drawdown | -0.97 | 3.07 | -4.04 |
| Martin ratioReturn relative to average drawdown | -1.31 | 17.37 | -18.67 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| LABD | XTJL | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -1.06 | 2.12 | -3.18 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.43 | — | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.59 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.54 | 0.65 | -1.19 |
Drawdowns
LABD vs. XTJL - Drawdown Comparison
The maximum LABD drawdown since its inception was -99.99%, which is greater than XTJL's maximum drawdown of -23.24%. Use the drawdown chart below to compare losses from any high point for LABD and XTJL.
Loading charts...
Drawdown Indicators
| LABD | XTJL | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.99% | -23.24% | -76.75% |
Max Drawdown (1Y)Largest decline over 1 year | -83.21% | -5.12% | -78.09% |
Max Drawdown (3Y)Largest decline over 3 years | -95.31% | -16.70% | -78.61% |
Max Drawdown (5Y)Largest decline over 5 years | -98.24% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -99.98% | — | — |
Current DrawdownCurrent decline from peak | -99.99% | 0.00% | -99.99% |
Average DrawdownAverage peak-to-trough decline | -90.92% | -4.04% | -86.88% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 61.36% | 0.90% | +60.46% |
Volatility
LABD vs. XTJL - Volatility Comparison
Direxion Daily S&P Biotech Bear 3x Shares (LABD) has a higher volatility of 27.46% compared to Innovator U.S. Equity Accelerated Plus ETF - July (XTJL) at 0.33%. This indicates that LABD's price experiences larger fluctuations and is considered to be riskier than XTJL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| LABD | XTJL | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 27.46% | 0.33% | +27.13% |
Volatility (6M)Calculated over the trailing 6-month period | 61.67% | 5.72% | +55.95% |
Volatility (1Y)Calculated over the trailing 1-year period | 75.77% | 7.43% | +68.34% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 96.26% | 15.22% | +81.04% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 95.93% | 15.22% | +80.71% |
LABD vs. XTJL - Expense Ratio Comparison
LABD has a 1.06% expense ratio, which is higher than XTJL's 0.79% expense ratio.
Dividends
LABD vs. XTJL - Dividend Comparison
LABD's dividend yield for the trailing twelve months is around 6.45%, while XTJL has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
LABD Direxion Daily S&P Biotech Bear 3x Shares | 6.45% | 6.67% | 4.68% | 6.13% | 0.53% | 0.00% | 3.94% | 1.75% | 0.81% |
XTJL Innovator U.S. Equity Accelerated Plus ETF - July | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
LABD and XTJL have a correlation of -0.46, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LABD has higher volatility (27.46%) compared to XTJL (0.33%). In terms of maximum drawdown, LABD dropped -99.99% vs XTJL's -23.24%.
On 3-year performance, XTJL leads with 14.68% vs -49.85% for LABD. On fees, XTJL is cheaper at 0.79% per year. On volatility, XTJL has been the lower-risk option at 0.33%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 3-year period, XTJL has performed better with a 14.68% return vs -49.85%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
XTJL is cheaper with a 0.79% expense ratio, compared with 1.06% for LABD.
LABD has the higher dividend yield at 6.45%, compared with 0.00% for XTJL.
They also come from different issuers: Direxion and Innovator. Their fees differ too: 1.06% for LABD and 0.79% for XTJL.
XTJL currently has the higher Sharpe Ratio (2.12 vs -1.06), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for LABD and XTJL
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer